Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm ...

Please provide your email address to receive an email when new articles are posted on . Brixadi is the first long-acting buprenorphine injectable that is available in weekly and monthly doses.

In a randomized trial, both 100-mg and 300-mg monthly maintenance doses of extended-release buprenorphine improved opioid abstinence in patients with high-risk opioid use, with no new safety signals.

The trial, published in JAMA Internal Medicine, showed that mothers using the extended-release injection had higher rates of staying off illicit opioids compared to those taking daily sublingual ...

LUND, Sweden, June 25, 2024 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized, double-blind, Phase 3 ...

Monthly injections work great. Patients come in once a month, get their shot, and can focus on the rest of their treatment.” — Samantha Callister, Executive Director Integrity Treatment Partners ...